Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company that specializes in discovering, developing, and commercializing drugs for severe metabolic, oncologic, and neuropsychiatric disorders. Their flagship product, Korlym, is an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome. The company is also developing relacorilant and nab-paclitaxel for the treatment of Cushing's syndrome and advanced ovarian tumors, respectively. Additionally, they are working on selective cortisol modulators for metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain. These products form the core of their revenue generation, catering to patients with specific medical needs.

Products

• Korlym (mifepristone) tablets

• Relacorilant

• Nab-paclitaxel

• Selective cortisol modulators